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Objectives: The study assessed markers of renal health in HIV/HBV co-infected patients receiving TDF- 
containing antiretroviral therapy in Ghana. 
Methods: Urinary protein-to-creatinine ratio (uPCR) and albumin-to-protein ratio (uAPR) were measured 
cross-sectionally after a median of four years of TDF. At this time, alongside extensive laboratory testing, 
patients underwent evaluation of liver stiffness and blood pressure. The estimated glomerular ﬁltration 
rate (eGFR) was measured longitudinally before and during TDF therapy. 
Results: Among 101 participants (66% women, median age 44 years, median CD4 count 572 cells/mm 3 ) 
21% and 17% had detectable HIV-1 RNA and HBV DNA, respectively. Overall 35% showed hypertension, 
6% diabetes, 7% liver stiffness indicative of cirrhosis, and 18% urinary excretion of Schistosoma antigen. 
Tubular proteinuria occurred in 16% of patients and was independently predicted by female gender and 
hypertension. The eGFR declined by median 1.8 ml/min/year during TDF exposure (IQR −4.4, −0.0); more 
pronounced declines ( ≥5 ml/min/year) occurred in 22% of patients and were associated with receiv- 
ing ritonavir-boosted lopinavir rather than efavirenz. HBV DNA, HBeAg, transaminases, and liver stiffness 
were not predictive of renal function abnormalities. 
Conclusions: The ﬁndings mandate improved diagnosis and management of hypertension and suggest 
targeted laboratory monitoring of patients receiving TDF alongside a booster in sub-Saharan Africa. 
© 2018 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Tenofovir disoproxil fumarate (TDF), the prodrug of the nu-
leotide analogue reverse transcriptase inhibitor (NRTI) tenofovir,
s active against both HIV and HBV. TDF use as part of antiretro-
iral therapy (ART) carries a risk of proximal tubular dysfunction
nd declining glomerular ﬁltration rate (GFR), 1–3 and monitoring of
enal function is recommended during treatment. 4,5 The risk is re-
ated to both level and length of TDF exposure and is enhanced by
o-administration of pharmacological boosters (e.g., ritonavir), low∗ Corresponding author. 
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avidR.Chadwick@stees.nhs.uk (D. Chadwick), Alessandra.Ruggiero@liverpool.ac.uk 
A. Ruggiero), frank.post@kcl.ac.uk (F. Post), geretti@liverpool.ac.uk (A. Geretti). 
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 http://creativecommons.org/licenses/by/4.0/ ) ody weight, and pre-existing chronic kidney disease (CKD). 6–10 
hilst TDF discontinuation is generally associated with improved
enal function, longer exposure and lower GFR at TDF interruption
redict a reduced likelihood of GFR recovery. 6 
Whilst in North America and Western Europe tenofovir alafe-
amide fumarate (TAF) provides a recommended alternative for-
ulation with a reduced potential for renal toxicity, 4,5 TAF is not
urrently available in resource-limited settings. The World Health
rganisation (WHO) recommends TDF as the preferred NRTI for
he treatment of HIV and HIV/HBV positive individuals in sub-
aharan Africa (SSA). 11 There are limited data on the occurrence
f TDF-related renal adverse events in African populations and
nly a few reported long-term data. A study from Malawi, South
frica, and Zimbabwe showed similar rates of renal events over
96 weeks in patients randomised to either TDF plus emtricitabinen Association. This is an open access article under the CC BY license. 
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m  (FTC) or zidovudine (ZDV) plus lamivudine (3TC), each in combi-
nation with efavirenz (EFV). 12 A cross-sectional study among HIV-
positive subjects who had received ART for a median of 9.3 years
in Uganda similarly found no differences in renal function when
comparing regimens with and without TDF. 13 Neither study as-
sessed the inﬂuence of concomitant use of ritonavir-boosted pro-
tease inhibitors (PI/r) or HBV co-infection on renal health. Short-
term studies reported an increased risk of renal abnormalities with
concomitant use of TDF and PI/r in SSA. In South Africa, HIV-1
positive adults on TDF experienced a small but signiﬁcant decline
in eGFR over a median of 13 months, and the decline was larger
with concomitant PI use, older age, weight < 60 kg, lower base-
line eGFR, and CD4 counts < 200 cells/mm 3 . 9 In women receiving
TDF in combination with either lopinavir/ritonavir (LPV/r) or nevi-
rapine (NVP), renal events were predicted by LPV/r use, baseline
HIV-1 RNA load, and baseline eGFR. 7 
By 2030, the number of patients requiring second-line ART in
SSA is estimated to exceed 4 million, and an increasing number is
likely to start therapy with PI/r. 14 At the same time, improved sur-
vival among people living with HIV in SSA is unmasking a substan-
tial burden of co-morbidities, including HBV co-infection. 15 Lim-
ited data suggest that chronic hepatitis B may worsen renal out-
comes. In one study in Zambia, HBV co-infection nearly doubled
the odds of a reduced eGFR after adjusting for several factors, and
the risk was higher among patients with raised serum transami-
nases. 16 Whilst the observation suggests a link between HBV dis-
ease activity and risk of renal dysfunction, published evidence has
not been consistent. 17 
The aim of this study was to evaluate the renal func-
tion of HIV/HBV co-infected individuals receiving long-term TDF-
containing ART in Ghana, integrating cross-sectionally measured
tubular proteinuria (TuPr) and prospectively measured eGFR with
markers of HIV and HBV status, and analysing the contributing role
of PI/r use, hypertension, and diabetes. 
Methods 
Setting 
Eligible HIV/HBV co-infected positive adults ( ≥18 years) were
drawn from the HEPIK (Hepatitis B Infection in Kumasi) prospec-
tive observational cohort based at the Komfo Anokye Teaching
Hospital (KATH) in Kumasi, Ghana. 18,19 The cohort was established
in 2010. Study visits took place at least once a year when partic-
ipants underwent clinical assessment and sample collection. The
last study visit occurred in November 2015. At study entry, upon
detection of HBV co-infection, patients introduced TDF; subse-
quent management was at the discretion of the treating clini-
cian. Between 2010 and 2015, monitoring for HIV-positive patients
at KATH comprised routine measurements of haemoglobin, serum
hepatic transaminases, and CD4 cell counts, and sporadic measure-
ments of serum creatinine. Urine dipstick analysis, measurement of
blood pressure in asymptomatic patients, and HIV/HBV virological
monitoring were not part of routine care. No patient had access
to TAF and TAF remains unavailable in Ghana in 2018. Ethical ap-
proval was granted by the Kwame Nkrumah University of Science
and Technology, Ghana; all patients gave written informed consent.
Study population 
The analysis comprised HEPIK participants who at the last
study visit (November 2015) were on stable TDF-containing
ART. At this time, patients underwent study-related clinical as-
sessment and sample collection. Adherence to ART was self-
reported through an ordinal visual scale graded from 0 to 100%,n 10% increments. Transient elastography was performed us-
ng Fibroscan (Ecosens, France) and interpretative cut-offs ap-
lied as previously reported. 19,20 Blood pressure (BP) was mea-
ured with a manual sphygmomanometer; abnormal ﬁndings
ere conﬁrmed after the patient had rested for ≥20 min. Hy-
ertension was graded as 1 (systolic 140–159 or diastolic 90–
9 mmHg), 2 (systolic 160–179 or diastolic 100–109 mmHg) and
 (systolic ≥180 or diastolic ≥110 mmHg). 21 Systolic BP < 140
nd/or diastolic BP < 90 mmHg on antihypertensive therapy was
cored as grade 1. Diabetes was deﬁned by glycated haemoglobin
HbA1c) ≥48 mmol/mol or receiving antidiabetic therapy. 
aboratory tests 
Serum alanine aminotransferase (ALT) and aspartate amino-
ransferase (AST), haemoglobin, and CD4 cell counts were mea-
ured at the KATH diagnostic laboratory. Laboratory reference
anges are shown in Supplementary Table 1 . Urine samples under-
ent dipstick analysis for proteinuria, haematuria, and glycosuria
ith Medi-Test Combi 5S (BHR Pharmaceuticals, Nuneaton, UK),
nd testing for Schistosoma circulating cathodic antigen (Ag) with
he Urine-CCA Cassette test (Rapid Medical Diagnostics, Pretoria,
outh Africa). 22 Plasma was separated from whole blood in EDTA
ithin one hour of collection and stored immediately at −80 °C.
rozen aliquots of whole EDTA blood, plasma, serum, and urine
ere shipped to the UK for further testing. In the UK, plasma HIV-
 RNA and HBV DNA were quantiﬁed by the RealTime HIV-1 and
BV assays (Abbott Diagnostics, Maidenhead, UK), as previously
escribed. 19 Hepatitis B e antigen (HBeAg) was measured by Archi-
ect (Abbott Diagnostics). Creatinine, urinary protein-to-creatinine
atio (uPCR), urinary albumin-to-creatinine ratio (uACR, performed
f uPCR > 20 mg/mmol), and HbA1c were measured in the accred-
ted diagnostic laboratory of the Royal Liverpool University Hos-
ital, Liverpool, UK. TuPr was deﬁned as uPCR > 20 mg/mmol
ith uACR/uPCR ratio < 0.4; 23 signiﬁcant TuPr was deﬁned by
PCR > 30 mg/mmol with uACR/uPCR ratio < 0.4. The eGFR was
alculated using the CKD epidemiology collaboration-derived equa-
ion (CKD-EPI); the ethnicity factor was applied (x1.21). 24 Reduc-
ion in eGFR was classed as grade 2, 3, or 4 based on readings
f 60–89, 30–59, and < 30 ml/min/1.73 m 2 , respectively. 21 In addi-
ion to blood samples collected in November 2015, stored samples
ollected between 2010 and 2015 were retrieved and serum crea-
inine was measured retrospectively to calculate changes in eGFR
ver time. A rapid eGFR decline (RD-eGFR) was deﬁned as a mean
ecline > 5 ml/min/1.73 m 2 /year. 10 
nalysis 
Patients’ characteristics according to the presence or absence of
uPr or RD-eGFR were compared by the Fisher’s, Chi-squared, or
ann–Whitney–Wilcoxon test, as appropriate. Factors associated
ith TuPr or RD-eGFR and factors associated with changes in eGFR
ver time were investigated in logistic and linear regression analy-
es, respectively. Each multivariable model explored factors asso-
iated with renal outcomes by stepwise selection. TuPr was not
ncluded in the analysis of factor associated with eGFR variation
nd vice versa, as potential collinearity between the two could
ot be excluded. This approach resulted in the inclusion of gen-
er and hypertension for TuPr; receipt of LPV/r and CD4 cell count
or changes in eGFR; and receipt of LPV/r, duration of HIV diagno-
is, and CD4 cell count for RD-eGFR. The robustness of the results
as investigated in models that serially added all variables show-
ng p < 0.2 in the univariate analysis, including Schistosoma Ag test,
iver stiffness, AST, and HbA1c for TuPr; ALT for changes in eGFR;
nd adherence for RD-eGFR. Haemoglobin was not included in the
ultivariable model for RD-eGFR as potentially part of the casual
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Table 1 
Characteristics of HIV/HBV positive patients with long-term TDF exposure according to the detection of tubular proteinuria (TuPr; n = 101 evaluated) and rapidly declining 
estimated glomerular ﬁltration rate (RD-eGFR; n = 97 evaluated). a 
Total With TuPr Without TuPr p With RD-eGFR Without RD-eGFR p 
N = 101 N = 16 N = 85 N = 21 N = 76 
Female gender, n (%) 67 (66.3) 15 (93.8) 52 (61.2) 0.01 16 (76.2) 48 (63.2) 0.31 
Age, median years (IQR) 44 (39, 48) 47 (38, 52) 44 (39, 48) 0.63 44 (40, 47) 45 (39, 48) 0.45 
BMI, median kg/m 2 (IQR) 23.5 (20.4, 27.3) 23.4 (20.7, 28.1) 23.5 (20.4, 27.1) 0.84 22.6 (20.8, 28.6) 23.3 (20.1, 27.1) 0.54 
Duration HIV diagnosis, median years (IQR) 8.3 (6.6, 10.2) 8.2 (6.6, 9.4) 8.4 (6.6, 10.3) 0.96 7.5 (5.3, 9.4) 8.4 (6.9, 10.3) 0.16 
ART duration, median years (IQR) 7.9 (6.0, 9.2) 7.9 (5.2, 8.8) 7.8 (6.3, 9.3) 0.71 7.4 (5.1, 8.8) 7.9 (6.2, 9.2) 0.40 
TDF duration, median years (IQR) 4.0 (3.8, 4.1) 4.0 (3.8, 4.1) 4.0 (3.8, 4.1) 0.45 4.0 (3.8, 4.2) 4.0 (3.8, 4.1) 0.99 
Prior ZDV, n (%) 89 (88.1) 14 (87.5) 75 (88.2) 1.00 19 (90.5) 67 (88.2) 1.00 
Prior d4T, n (%) 48 (47.5) 8 (50.0) 40 (47.1) 1.00 7 (33.3) 39 (51.3) 0.22 
Receiving EFV, n (%) 87 (86.1) 15 (93.8) 72 (84.7) 0.50 12 (57.1) 72 (94.7) < 0.001 
Receiving NVP, n (%) 4 (4.0) 0 (0) 4 (4.7) 1.00 4 (19.1) 0 (0) 0.02 
Receiving LPV/r, n (%) 10 (9.9) 1 (6.3) 9 (10.6) 1.00 5 (23.8) 4 (5.3) 0.02 
Adherence ≥90%, n (%) 86 (86.9) 15 (93.8) 71 (83.5) 0.69 16 (76.2) 66 (86.8) 0.15 
Haemoglobin, median g/dl (IQR) 13.2 (11.6, 14.6) 12.0 (11.1, 14.4) 13.2 (11.7, 14.7) 0.34 11.7 (11.4, 13.7) 13.4 (11.8, 14.7) 0.07 
CD4 count, median cells/mm 3 (IQR) 572 (383, 716) 593 (302, 639) 565 (391, 717) 0.47 572 (391, 749) 559 (370, 711) 0.78 
HIV-1 RNA > 40 copies/ml, n (%) 21 (20.8) 4 (25.0) 17 (20.0) 0.74 6 (28.6) 14 (18.4) 0.36 
HIV-1 RNA > 10 0 0 copies/ml, n (%) 14 (13.9) 3 (18.8) 11 (12.9) 0.69 2 (9.5) 12 (15.8) 0.73 
HBV DNA > 15 IU/ml, n (%) 15 (14.9) 2 (12.5) 13 (15.3) 1.00 3 (14.3) 11 (14.7) 1.00 
HBV DNA > 20 0 0 IU/ml, n (%) 6 (5.9) 1 (6.3) 5 (5.9) 1.00 3 (14.3) 3 (4.0) 0.11 
Liver stiffness, median kPa (IQR) 4.6 (3.8, 5.8) 4.8 (3.1, 5.5) 4.5 (3.8, 5.9) 0.86 4.6 (3.9, 6.1) 4.6 (3.8, 5.7) 0.87 
Liver stiffness kPa > 9.4, n (%) 7 (6.9) 2 (12.5) 5 (5.9) 0.29 1 (4.8) 5 (6.6) 1.00 
AST, median IU/l (IQR) 31 (23, 38) 31 (22, 39) 27 (25, 35) 0.83 30 (24, 37) 31 (23, 39) 0.98 
ALT, median IU/l (IQR) 24 (18, 33) 23 (16, 30) 24 (18, 36) 0.42 26 (17, 32) 24 (18, 36) 0.89 
HBeAg positive, n (%) 11 (10.9) 1 (6.3) 10 (11.8) 0.63 3 (14.3) 8 (10.5) 0.61 
Systolic BP, median mmHg (IQR) 122 (112, 145) 148 (122, 160) 121 (110, 137) < 0.01 126 (118, 130) 122 (110, 147) 0.64 
Diastolic BP, median mmHg (IQR) 80 (71, 90) 90 (77, 110) 80 (70, 88) 0.02 78 (74, 86) 80 (70, 93) 0.90 
Hypertension, n (%) Any grade 35 (35.0) 10 (62.5) 25 (29.4) 0.02 6 (28.6) 28 (36.8) 0.61 
Grade 1 13 (13.0) b 2 (12.5) 11 (12.9) – 2 (9.5) 11 (14.5) –
Grade 2 12 (12.0) 3 (18.8) 9 (10.6) – 2 (9.5) 10 (13.2) –
Grade 3 10 (10.0) 5 (31.3) 5 (5.9) – 2 (9.5) 7 (9.2) –
NA 1 (1.0) 0 (0) 1 (1.2) – 0 (0) 0 (0) –
Hb1Ac, median mmol/mol (IQR) 33 (31–38) 35 (31, 38) 33 (31, 38) 0.55 34 (32, 39) 33 (30, 38) 0.15 
Diabetes, n (%) 6 (5.9) c 2 (12.5) 4 (4.7) 0.24 2 (9.5) 4 (5.3) 0.61 
Schistosoma Ag positive, n (%) 18 (17.8) 5 (31.3) 13 (15.3) 0.16 5 (23.8) 12 (15.8) 0.52 
a TuPr proteinuria was deﬁned as uPCR ≥20 mg/mmol and uACR/uPCR < 0.4; RD-eGFR was deﬁned as ≥5 ml/min eGFR decline per year. 
b Comprising 4 subjects with normal readings while on anti-hypertensive medication. 
c Comprising 2 subjects with normal readings while on oral hypoglycaemic medication. uPCR = urinary protein/creatinine ratio; uACR = urinary albumin/creatinine ra- 
tio; IQR = interquartile range; BMI = body mass index; ART = antiretroviral therapy; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine; d4T = stavudine; EFV = efavirenz; 
NVP = nevirapine; LPV/r = ritonavir-boosted lopinavir; AST = aspartate transaminase; ALT = alanine transaminase; BP = blood pressure; NA = not available; Hb1Ac = glycated 
haemoglobin; Ag = Antigen. 
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(  athway of the outcome. The distribution of residuals was assessed
or each linear regression, and indicated a good model ﬁt. Perfor-
ance of dipstick proteinuria ( ≥0.3 g/l), glycosuria (1.1 mmol/l)
nd haematuria ( ≥10 cells/μl) as predictors of TuPr was estimated
hrough a receiver operating characteristic (ROC) analysis. Analyses
ere performed with STATA v.14. 
esults 
haracteristics of the study population 
The study population comprised 101 subjects that had received
DF for a median of 4.0 years (IQR 3.8–4.1) ( Table 1 ). All sub-
ects were also receiving 3TC and most were receiving EFV (87/101,
6.1%). Ten (9.9%) were on LPV/r, having received the PI/r for a me-
ian of 4.4 years (IQR 3.7–5.5). Plasma HIV-1 RNA was detected
n 21/101 (20.8%) subjects at median levels of 4.2 log 10 copies/ml
IQR 2.1–5.1). HBV DNA was detected in 15/101 (14.9%) subjects
t median levels of 2.7 log 10 IU/ml (IQR 1.7–3.8). Hypertension of
ny grade was diagnosed in 35/100 (35.0%) subjects. There were
/101 (8.9%) patients on anti-hypertensive drugs (nifedipine, losar-
an, bendroﬂumethiazide) and ﬁve of these had elevated blood
ressure of grade 1 ( n = 1), 2 ( n = 3), or 3 ( n = 1). Diabetes was di-
gnosed in 6/101 (5.9%) subjects. There were 3/101 (3.0%) patients
n oral hypoglycaemic drugs (metformin, glibenclamide) and one
f these had abnormal Hb1Ac levels (80 mmol/mol). The urinarychistosoma Ag was reactive in 18/101 (17.8%) subjects. None of the
articipants was taking other regular medications. 
arkers of renal health 
ubular proteinuria 
The uPCR was median 13 mg/mmol (IQR 13–20) and
as > 20 mg/mmol in 28/101 (27.7%) patients and > 50 mg/mmol
n 13/101 (12.9%) patients ( Table 2 ). Among subjects with
PCR > 20 mg/mmol, the uACR was median 0.33 mg/mmol (IQR
.17–0.49). TuPr was diagnosed in 16/101 (15.8%) subjects, includ-
ng 9/101 (8.9%) with signiﬁcant TuPr ( Supplementary Table 2 ). TuPr
as signiﬁcantly more prevalent in women and patients with hy-
ertension and the association was conﬁrmed after adjustment
 Table 3 ). The univariate analysis showed trends for an association
etween TuPr and higher liver stiffness, higher HbA1c levels, and
 positive Schistosoma Ag test. Separate models adjusting for these
ariables conﬁrmed that gender and hypertension were each inde-
endently associated with TuPr ( Supplementary Table 3 ). 
hanges in eGFR over time 
At the last study visit, the eGFR was median
03 ml/min/1.73 m 2 (IQR 92–116) and was < 90 ml/min in
2/101 (21.8%) subjects, including 4/101 (4.0%) subjects with lev-
ls < 30 ml/min ( Table 2 ). The analysis of changes in eGFR over
ime comprised 90 subjects with data from three time points
T0, T1, T2) and seven subjects with data from two time points
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Table 2 
Relationship between markers of renal health in HIV/HBV positive patients with long-term TDF exposure. 
Total With TuPr Without TuPr p With RD-eGFR Without RD-eGFR p 
N = 101 N = 16 N = 85 N = 21 N = 76 
Serum creatinine Median μmol/l 
(IQR) 
78 (66, 87) 74 (64, 81) 79 (67, 90) 0.11 82 (75, 103) 77 (64, 85) –
eGFR Median ml/min 
(IQR) 
103 (92, 116) 105 (88, 124) 103 (93, 116) 0.97 92.3 (81.3, 105) 107 (94.1, 117) –
≥90 ml/min n (%) 79 (78.2) 12 (75.0) 67 (78.8) 0.75 12 (57.1) 63 (82.9) –
60–89 ml/min n (%) 18 (17.8) 3 (18.8) 15 (17.7) 7 (33.3) 11 (14.5) –
30–60 ml/min n (%) 4 (4.0) 1 (6.3) 3 (3.5) 2 (9.5) 2 (2.6) –
Change over time Median ml/min 
(IQR) 
−1.8 ( −4.4, −0.0) −2.4 ( −5.8, −1.0) −1.7 ( −4.3, + 0.3) 0.49 −7.12 ( −7.48, −5.79) −1.20 ( −2.82, + 0.92) –
Rapid decline ( n = 97) n (%) 21 (21.6) 4 (25.0) 17 (20.0) 0.12 21 (100) 0 (0) –
uPCR Median mg/mmol 
(IQR) 
13 (10, 20) 32 (24, 56) 12 (9, 17) – 13 (9, 18) 14 (10, 21) 0.30 
> 20 mg/mmol n (%) 28 (27.7) 16 (100) 12 (14.1) – 5 (23.8) 21 (27.6) 1.00 
≥50 mg/mmol n (%) 13 (12.9) 5 (31.3) 8 (9.4) – 3 (14.3) 10 (13.2) 1.00 
Tubular proteinuria n (%) 16 (15.8) 16 (100) 0 (0) – 4 (19.1) 10 (13.2) 0.50 
Dipstick protein n (%) 15 (14.9) 4 (25.0) 11 (12.9) 0.25 3 (14.3) 12 (15.8) 1.00 
Dipstick RBC n (%) 12 (11.9) 5 (31.3) 7 (8.2) 0.02 3 (14.3) 8 (10.5) 0.70 
Dipstick glucose n (%) 17 (16.8) 4 (25.0) 13 (15.3) 0.46 5 (23.8) 11 (14.5) 0.33 
TuPr = tubular proteinuria; RD-eGFR = rapid declining estimated glomerular ﬁltration rate; IQR = inter-quartile range; uPCR = urinary protein/creatinine ratio; RBC = red blood 
cells. 
Table 3 
Logistic regression analysis of factors associated with TuPr and RD-eGFR in HIV/HBV positive patients with long-term TDF exposure. a 
Factors associated with TuPr Factors associated with RD-eGFR 
Univariate analysis Multivariable analysis a Univariate analysis Multivariable analysis a 
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p 
Gender Female vs. male 9.52 1.20, 75.5 0.03 9.65 1.19, 78.5 0.03 1.87 0.62, 5.65 0.27 
Age Per 5 years older 1.14 0.81, 1.60 0.46 0.88 0.64, 1.21 0.43 
BMI Per kg/m 2 higher 1.00 0.90, 1.12 0.95 1.03 0.94, 1.14 0.50 
Duration HIV diagnosis Per year longer 0.96 0.77, 1.21 0.74 0.85 0.69, 1.06 0.15 0.83 0.66, 1.05 0.12 
ART duration Per year longer 0.93 0.74, 1.17 0.53 0.90 0.73, 1.13 0.37 
TDF duration Per year longer 0.66 0.18, 2.42 0.53 0.80 0.26, 2.46 0.70 
Third antiretroviral LPV/r vs. NNRTI 0.56 0.07, 4.78 0.60 5.63 1.36, 23.3 0.02 6.14 1.42, 26.5 0.02 
Adherence ≥90% vs. < 90% 2.54 0.31, 21.0 0.39 0.39 0.11, 1.35 0.14 
Haemoglobin Per g/dl higher 0.90 0.74, 1.10 0.30 0.84 0.68, 1.03 0.09 
CD4 count Per 50 cells/mm 3 higher 0.96 0.86, 1.06 0.42 1.02 0.93, 1.11 0.70 
HIV-1 RNA Per log 10 copies/ml higher 1.10 0.70, 1.72 0.68 0.89 0.56, 1.42 0.63 
HBV DNA Per log 10 IU/ml higher 0.88 0.45, 1.72 0.70 1.21 0.81, 1.82 0.36 
Liver stiffness Per one kPa higher 1.05 0.98, 1.14 0.16 1.04 0.97, 1.11 0.23 
AST Per 10 IU/l higher 0.75 0.49, 1.15 0.19 1.05 0.84, 1.31 0.64 
ALT Per 10 IU/l higher 1.06 0.83, 1.35 0.65 0.92 0.68, 1.25 0.61 
HBeAg Yes vs. no 0.52 0.06, 4.40 0.55 1.46 0.35, 6.08 0.61 
Hypertension Yes vs. no 3.93 1.29, 12.0 0.02 3.51 1.08, 11.4 0.04 0.69 0.24, 1.97 0.48 
Hb1Ac Per 5 mmol/mol higher 1.16 0.95, 1.42 0.14 1.06 0.89, 1.27 0.52 
Diabetes Yes vs. no 2.89 0.48, 17.3 0.25 1.89 0.32, 11.1 0.48 
Schistosoma Ag Positive vs. negative 2.52 0.75, 8.45 0.14 1.67 0.51, 5.42 0.40 
a Variables were identiﬁed for inclusion in the multivariable model using stepwise selection (p value entry and exit < 0.2); the multivariable analysis of RD-eGFR excluded 
haemoglobin; OR = odds ratio; CI = conﬁdence interval; BMI = body mass index; ART = antiretroviral therapy; TDF = tenofovir disoproxil fumarate; LPV/r = ritonavir-boosted 
lopinavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; AST = aspartate transaminase; ALT = alanine transaminase; Hb1Ac = glycated haemoglobin; Ag = antigen. 
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2  (T0 and T2). T0 occurred prior to TDF introduction (median −0.2
months; IQR −2.2, −0.1), whereas T1 and T2 occurred a median
of 8.1 months (IQR 5.9–10.9) and 4.0 years (IQR 3.8–4.1) after
TDF introduction, respectively. By univariate linear regression
analysis, receiving LPV/r at T2 was associated with a larger eGFR
decline, and the association persisted after adjusting for CD4 cell
counts ( Table 4 ). Of the total population on LPV/r, four subjects
had started LPV/r prior to T0, ﬁve between T0 and T1, and one
between T1 and T2. The univariate analysis indicated a trend for
an association between changes in eGFR and ALT levels. A separate
model adjusting for CD4 cell counts and ALT levels conﬁrmed the
independent association between LPV/r and eGFR decline (coeﬃ-
cient −3.31; 95% CI −5.87, −0.75; p = 0.01); no other independent
predictors were identiﬁed (not shown). 
A diagnosis of RD-eGFR was made in 21/97 (21.6%) subjects. Pa-
tients with RD-eGFR were more likely to be receiving LPV/r, and
the association persisted after adjustment ( Table 3 ). Among theour subjects with eGFR < 60 ml/min at T2, two had experienced
D-eGFR, whereas the other two had a low eGFR at T0. In the main
ogistic regression model, receiving LPV/r independently increased
he risk of RD-eGFR after adjusting for duration of HIV diagnosis.
 separate model also adjusting for adherence conﬁrmed the ﬁnd-
ngs with an odds ratio (OR) of 5.27 (95% CI 1.13–24.5; p = 0.03)
not shown). 
elationship between TuPr, eGFR, and urinary dipstick results 
Median eGFR and prevalence of eGFR < 90 ml/min were similar
n subjects with and without TuPr ( Table 2 ). Changes in eGFR were
lightly greater in subjects with TuPr (median −2.4 ml/min/year)
han in those without TuPr (median −1.7 ml/min/year). As a result,
 diagnosis of RD-eGFR was made in a slightly larger proportion of
ubjects with TuPr (4/16; 25.0%) than in those without TuPr (17/85;
0.0%). Patients with TuPr showed increased prevalence of dipstick
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Table 4 
Linear regression analysis of factors associated with changes in eGFR in HIV/HBV positive patients with long-term TDF exposure. 
Univariate analysis Multivariable analysis a 
Coeﬃcient 95% CI p Coeﬃcient 95% CI p 
Gender Female vs. male −0.55 −2.14, + 1.04 0.50 
Age Per 5 years older + 0.02 −0.07, + 0.12 0.63 
BMI Per kg/m 2 higher + 0.04 −0.11, + 0.20 0.57 
Duration HIV diagnosis Per year longer −0.02 −0.36, + 0.33 0.93 
ART duration Per year longer −0.12 −0.46, + 0.22 0.48 
TDF duration Per year longer −1.16 −3.65, + 1.33 0.36 
Third antiretroviral LPV/r vs. NNRTI −3.12 −5.64, −0.60 0.02 −3.51 −6.04, −0.98 0.01 
Adherence ≥90% vs. < 90% + 1.12 −1.10, + 3.34 0.32 
Haemoglobin Per g/dl higher + 0.13 −0.15, + 0.41 0.35 
CD4 count Per 50 cells/mm 3 higher −0.09 −0.23, + 0.05 0.20 −0.12 −0.26, + 0.01 0.08 
HIV-1 RNA Per log 10 copies/ml higher + 1.02 −1.11, + 3.16 0.34 
HBV DNA Per log 10 IU/ml higher −0.22 −0.95, + 0.51 0.55 
Liver stiffness Per kPa higher + 0.10 −0.24, + 0.44 0.56 
AST Per 10 IU/l higher −0.10 −0.47, + 0.27 0.61 
ALT Per 10 IU/l higher + 0.31 −0.13, + 0.76 0.17 
HBeAg Yes vs. no −0.52 −2.91, + 1.87 0.67 
Hypertension Yes vs. no −0.01 −1.59, + 1.57 0.99 
Hb1Ac Per 5 mmol/mol higher + 0.02 −0.13, + 0.16 0.83 
Diabetes Yes vs. no −0.61 −3.74, + 2.52 0.70 
Schistosoma Ag Positive vs. negative −0.36 −2.35, + 1.62 0.72 
a All variables with p < 0.20 in the univariate analysis were considered for inclusion using a stepwise selection with p 
of exit < 0.2; CI = conﬁdence interval; BMI = body mass index; ART = antiretroviral therapy; LPV/r = ritonavir-boosted lopinavir; 
NNRTI = non-nucleoside reverse-transcriptase inhibitor; AST = aspartate transaminase; ALT = alanine transaminase; Hb1Ac = glycated 
haemoglobin. 
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v  aematuria, and to a lesser extent increased prevalence of dipstick
roteinuria. The ROC analysis indicated poor agreement between
uPr and dipstick proteinuria, glycosuria and haematuria, with an
rea under the curve ( r ) of 0.56, 0.55, and 0.61, respectively ( Sup-
lementary Figure 1 ). A diagnosis of RD-eGFR was not associated
ith clear dipstick patterns, although prevalence of glycosuria was
igher than in patients without RD-eGFR. A detailed summary of
rinary dipstick results in relation to a diagnosis of TuPr, RD-GFR,
ypertension, diabetes, or Schistosoma Ag positivity is presented in
upplementary Table 4 . 
iscussion 
Among HIV/HBV co-infected subjects on long-term TDF-
ontaining ART prevalence of TuPr was 15.8%, and the risk was
ighest among women and those with hypertension. There was
n overall modest eGFR decline over time (1.8 ml/min per year of
DF), but 21.6% of participants experienced a more pronounced de-
line ( ≥5 ml/min per year). Despite the small number of patients
n LPV/r, a strong association was detected between a larger eGFR
ecline and receiving LPV/r. There was limited overlap between
uPr and RD-eGFR, pointing at the different impact of promoting
actors. In addition, there was no clear evidence of an effect of HBV
isease activity on the two renal markers, as expressed by HBV
NA load, HBeAg status, transaminase levels, and liver stiffness.
rinary dipstick failed to accurately predict TuPr, although was
ble to point to important co-morbidities (i.e., proteinuria with hy-
ertension and schistosomiasis, glycosuria with hypertension and
iabetes). 
Previous studies conducted predominantly in HIV-positive pa-
ients of white ethnicity reported tubular dysfunction in 7-22%
f subjects receiving TDF-containing ART for up to nearly ﬁve
ears. 25–28 Prevalence of TuPr in the Kumasi cohort after a me-
ian of four years of TDF was close to the upper limit of the re-
orted range, and hypertension increased the risk by over four-
old. There is a growing burden of hypertension across West Africa,
nd whilst the determinants remain to be fully established, the at-
ributable mortality is estimated to have increased by over 100%
etween 1990 and 2015. 29 The prevalence of diagnosed hyperten-ion can reach 54% in the general population 30 and hypertension
s estimated to account for 32% of all cases of CKD in Ghana. 31 
 third of patients in our study had hypertension, although only
 few reported a previous diagnosis and fewer still were receiv-
ng anti-hypertensive medication. A similar high rate of untreated
ypertension among HIV-positive patients has been reported from
ther regions of SSA. 32 While we found no evidence of related
linical events among patients still attending for care, the ﬁndings
learly highlight the urgent need to introduce routine blood pres-
ure screening in African HIV care settings. 
There was also a strong association between TuPr and female
ender, although the large conﬁdence interval prevented an ac-
urate estimation of the magnitude of the risk. Previous studies
nvestigating factors associated with tubulopathy in HIV-positive
ubjects did not identify an effect of gender but included predomi-
antly Caucasian males. 26,33 , 34 An association between female gen-
er and risk of renal disease has been described, which may reﬂect
he inﬂuence of sex hormones on several biological processes in-
olved in kidney injury. 35 It could also be speculated that greater
dherence or lower body weight among women may have in-
reased TDF exposure relative to men, increasing the risk of tubu-
opathy. In SSA, women have been reported to have greater ad-
erence to ART than men 36 and a similar trend was present in
ur cohort, with adherence rates ≥90% by visual scale reported
n 91% of women and 79% of men respectively. The BMI how-
ver did not show an association with renal abnormalities, being
igher in women than in men (24.2 vs. 21.4 km/m 2 ). Data from
igger cohorts are needed to conﬁrm the role of gender in increas-
ng the risk of tubular proteinuria among HIV-positive people on
DF-containing ART. 
A previous study of the general population in the same re-
ion of Ghana showed that approximately 2% of adults (mean age
5 years) had an eGFR < 60 ml/min. 37 This compares with a preva-
ence of 4% in our study, where the mean age was 45 years, sug-
esting a greater burden of renal disease. It should be noted that
fter a median of four years of exposure to TDF, there was only a
odest decline in eGFR, which is in line with the reported overall
ood safety proﬁle of TDF. 38 Importantly, and consistent with pre-
ious data, 7,9 there was evidence that the eGFR decline was greater
520 G. Villa et al. / Journal of Infection 76 (2018) 515–521 
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 in patients receiving LPV/r. Concomitant treatment with LPV/r may
indirectly increase the risk of renal damage by boosting TDF expo-
sure through reduced excretion or increased reabsorption, whilst
other PIs may have a more direct nephrotoxic potential. 39 As the
impact of concomitant PI may differ by type, it will be important
to monitor the relative impact of atazanavir and darunavir, which
are becoming available across SSA. 40 
CKD is estimated to have an overall prevalence of 14% across
populations of SSA, although attention has been drawn to the poor
quality of the data and the need for more information using vali-
dated measures of kidney function. 30 In addition to the direct ef-
fect of poorly controlled HIV, rising prevalence of CKD in SSA may
be fuelled by increasing urbanisation, dietary changes, and grow-
ing rates of tobacco consumption, obesity, diabetes and hyperten-
sion acting on a background of longer life-expectancy 30 and ge-
netic predisposition to renal disease. 41 There are limited data sug-
gesting that diabetes is a signiﬁcant contributor to renal disease
in HIV-positive African cohorts. 30,42 Although numbers were small,
in our study there appeared to be a role for diabetes as a deter-
minant of renal abnormalities, again pointing at the importance of
screening for co-morbidities in HIV care settings. 
A previous study suggested a role for HBV co-infection in in-
creasing the risk of renal disease in Zambian HIV-positive adults. 16 
Reassuringly, we detected no indication that HBV status increased
the risk of renal function abnormalities. Among infectious co-
morbidities with a potential impact on renal health, high rates of
Schistosoma infection may play a role in Ghana. In Kumasi, preva-
lence rates of 21% have been described among hospital attendees,
although varying considerably according to likelihood of exposure
to contaminated water. 43 S. haematobium, which causes chronic
infection of the urinary tract tends to prevail over S. mansoni , 44 
although immunological-mediated impairment of glomerular and
tubular function has also been associated with infection by S. man-
soni . 45 Our data documented a reactive CCA-test in 17.8% of sub-
jects, which suggest a high burden of infection. A reactive CCA-
test was often accompanied by dipstick proteinuria and haema-
turia, and carried a 2.5-fold increase in the odds of tubular pro-
teinuria. Data are needed to ascertain the impact of speciﬁc Schis-
tosoma treatment on urinary ﬁndings. 
There are limitations of this study. As it is often the case with
cohorts in SSA, we observed a signiﬁcant loss to follow-up (26%)
and a documented mortality rate of at least 8% over ﬁve years.
While some subjects may have moved to a different part of the
country, most loss is believed to reﬂect undocumented mortality.
Patients with severe renal impairment or complications of undiag-
nosed hypertension or diabetes might have died, leading to an un-
derestimation of the burden of disease. Our data therefore should
be interpreted as providing estimates for patients who continued
to engage with HIV care. Tests not available in Kumasi were per-
formed on frozen samples and sample volume restricted the num-
ber of tests. Ideally, additional measures of tubular function and
explorative biomarkers of renal function might have been consid-
ered, while more frequent measurements of eGFR over time may
have allowed increased conﬁdence in the estimates. Further, a di-
agnosis of hypertension was based on two separate measurements
on the same day, and repeated measurements over time would
have improved diagnostic accuracy. Overall small study numbers
meant that conﬁdence intervals were wide, although associations
were controlled for carefully. Despite these limitations, the data
have important implications for the management of HIV-positive
patients in SSA, and identify several important research needs.
Among subjects retained into care, long-term TDF use appeared
overall safe, especially in the context of EFV-containing ART. Atten-
tion should be paid to optimising blood pressure control, starting
from the introduction of routine blood pressure monitoring. Regu-
lar measurements of eGFR should also be introduced, and priori-ised for patients receiving TDF with a booster. The use of urinary
ipstick was effective in detecting evidence of hypertension, dia-
etes and possible schistosomiasis, and should be included in rou-
ine care to improve diagnosis and management of prevalent co-
orbidities. In our cohort, one in ﬁve indi viduals had detectable
IV viral load, typically coinciding with a detectable HBV DNA, and
ptimising control of virus replication remains a key priority. For
atients with renal toxicity, where HBV co-infection and lack of
ntecavir make TDF discontinuation undesirable, reducing the dose
f TDF could potentially improve renal safety 46 . The potential cost-
eneﬁts of enabling access to TAF for HIV-positive patients in SSA
ho are at risk of progressive renal dysfunction remain to be de-
ermined. 
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